

FINANCIAL TEAR SHEET

CORPORATE PROFILE

Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.

PRIMARY IR CONTACT

Investor Relations
Phone: 647-479-9825
E-mail: ir@aptose.com

STOCK PERFORMANCE

APTO (COMMON STOCK)

Exchange	TSX (Canadian Dollar)
Price	Can\$1.80
Change (%)	0.00 (0.00%)
Volume	2,200
52 Week Low	Can\$1.05
Market Cap	Can\$43,499,286
Rolling EPS	-1.00
PE Ratio	0
Shares Outstanding	24,166,270
Data as of October 23, 2017 9:38 a.m. ET	



APTO (COMMON STOCK)

Exchange	NASDAQ CM (US Dollar)
Price	\$1.42
Change (%)	▼ 0.01 (0.70%)
Volume	46,535
52 Week Low	\$0.78
Market Cap	\$34,557,766
Rolling EPS	-0.77
PE Ratio	0
Shares Outstanding	24,166,270
Data as of October 23, 2017 9:49 a.m. ET	



RECENT PRESS RELEASES & UPCOMING EVENTS

September 19, 2017

Aptose to Present at the 17th Annual Biotech in Europe Forum

September 12, 2017

Aptose Biosciences and CrystalGenomics Announce Issuance of U.S. Patent for CG'806

September 5, 2017

Aptose Biosciences to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

There are currently no events scheduled.

SEC FILINGS

Filing Date	Form
September 19, 2017	6-K
September 12, 2017	6-K
September 5, 2017	6-K
August 9, 2017	6-K

CORPORATE GOVERNANCE

William G. Rice, Ph.D.	Chairman, President & Chief Executive Officer
Daniel D. Von Hoff, M.D., F.A.C.P.	Senior Vice President, Medical Affairs
Stephen B. Howell, M.D.	Acting Chief Medical Officer
Gregory Chow	Senior Vice President, Chief Financial Officer
Ernest Kitt	Vice President, Development and Technical Operations

Data provided by Nasdaq. Minimum 15 minutes delayed.